NASDAQ:GBT - Global Blood Therapeutics Price Target & Analyst Ratings Sign in or create an account to add this stock to your watchlist. Get Started $43.23 +0.46 (+1.08 %) (As of 12/12/2018 04:00 PM ET)Previous Close$42.77Today's Range$42.00 - $43.8852-Week Range$30.15 - $68.05Volume794,800 shsAverage Volume1.12 million shsMarket Capitalization$2.23 billionP/E Ratio-15.66Dividend YieldN/ABeta3.67 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Analyst Ratings Global Blood Therapeutics (NASDAQ:GBT) Price Target and Consensus Rating (How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.14 Wall Street analysts have issued ratings and price targets for Global Blood Therapeutics in the last 12 months. Their average twelve-month price target is $86.3571, suggesting that the stock has a possible upside of 99.76%. The high price target for GBT is $150.00 and the low price target for GBT is $61.00. There are currently 1 hold rating and 13 buy ratings for the stock, resulting in a consensus rating of "Buy."Today30 Days Ago90 Days Ago180 Days AgoConsensus Rating: BuyBuyBuyBuyConsensus Rating Score: 2.932.932.932.92Ratings Breakdown: 0 Sell Rating(s)1 Hold Rating(s)13 Buy Rating(s)0 Strong Buy Rating(s)0 Sell Rating(s)1 Hold Rating(s)13 Buy Rating(s)0 Strong Buy Rating(s)0 Sell Rating(s)1 Hold Rating(s)13 Buy Rating(s)0 Strong Buy Rating(s)0 Sell Rating(s)1 Hold Rating(s)11 Buy Rating(s)0 Strong Buy Rating(s)Consensus Price Target: $86.3571$83.1429$82.5714$72.4167Price Target Upside: 99.76% upside109.74% upside96.60% upside53.43% upsideGlobal Blood Therapeutics (NASDAQ:GBT) Consensus Price Target History Global Blood Therapeutics (NASDAQ:GBT) Analyst Ratings History Show: Only the Most Recent Rating From Each Brokerage All Ratings For This Stock DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails12/4/2018SunTrust BanksBoost Price TargetBuy ➝ Positive$90.00Medium12/4/2018HC WainwrightSet Price TargetBuy$150.00Medium12/3/2018William BlairReiterated RatingBuyHigh12/3/2018Cantor FitzgeraldSet Price TargetBuy$96.00High12/3/2018OppenheimerSet Price TargetBuy$82.00High11/19/2018WedbushReiterated RatingBuy$73.00Low8/13/2018CowenReiterated RatingBuy$83.00High8/6/2018Piper Jaffray CompaniesInitiated CoverageOverweight$80.00Low8/5/2018JPMorgan Chase & Co.Reiterated RatingBuy$75.00Low6/28/2018NomuraBoost Price TargetBuy ➝ Buy$91.00 ➝ $109.00High6/27/2018Wells Fargo & CoBoost Price TargetOutperform$78.00 ➝ $85.00High4/26/2018Needham & Company LLCReiterated RatingBuy$70.00High3/21/2018Morgan StanleyDowngradeOverweight ➝ Equal Weight$61.00High2/13/2018Janney Montgomery ScottInitiated CoverageBuy ➝ Buy$75.00Medium3/20/2017Roth CapitalSet Price TargetBuy$47.00Low3/1/2017InstinetInitiated CoverageBuy ➝ Buy$50.00N/A(Data available from 12/12/2016 forward) This page was last updated on 12/12/2018 by MarketBeat.com StaffFeatured Article: Why is the LIBOR significant?